Y-mAbs Therapeutics, Inc. Annual Deferred Income Tax Expense (Benefit) in USD from 2016 to 2022

Taxonomy & unit
us-gaap: USD
Description
Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.
Summary
Y-mAbs Therapeutics, Inc. quarterly/annual Deferred Income Tax Expense (Benefit) history and growth rate from 2016 to 2022.
  • Y-mAbs Therapeutics, Inc. Deferred Income Tax Expense (Benefit) for the quarter ending June 30, 2024 was $0.000.
  • Y-mAbs Therapeutics, Inc. annual Deferred Income Tax Expense (Benefit) for 2022 was -$18K, a 94.1% increase from 2021.
  • Y-mAbs Therapeutics, Inc. annual Deferred Income Tax Expense (Benefit) for 2021 was -$304K.
  • Y-mAbs Therapeutics, Inc. annual Deferred Income Tax Expense (Benefit) for 2020 was $0.000.
Deferred Income Tax Expense (Benefit), Trailing 12 Months (USD)
Deferred Income Tax Expense (Benefit), Annual (USD)
Deferred Income Tax Expense (Benefit), YoY Annual Growth (%)
Period Value YoY Chg Change % Start Date End Date Report Filed
2022 -$18K +$286K +94.1% Jan 1, 2022 Dec 31, 2022 10-K 2024-02-29
2021 -$304K -$304K Jan 1, 2021 Dec 31, 2021 10-K 2023-03-30
2020 $0 $0 Jan 1, 2020 Dec 31, 2020 10-K 2021-03-01
2019 $0 $0 Jan 1, 2019 Dec 31, 2019 10-K 2021-03-01
2018 $0 $0 Jan 1, 2018 Dec 31, 2018 10-K 2020-03-12
2017 $0 $0 Jan 1, 2017 Dec 31, 2017 10-K 2019-03-22
2016 $0 Jan 1, 2016 Dec 31, 2016 10-Q 2018-11-13
* An asterisk sign (*) next to the value indicates that the value is likely invalid.